Robert F. Kennedy Jr. critiques Ozempic promotion and highlights obesity root causes

Sponsored Ad

Former independent presidential candidate Robert F. Kennedy Jr. has criticized the promotion of Ozempic and similar medications, claiming that this focus diverts attention from the root causes of obesity. His comments were made in response to a New York Times opinion piece that he felt overlooked the issues of processed diets and mental health related to overeating.

Kennedy asserted that Novo Nordisk, the maker of Ozempic for Type 2 diabetes and Wegovy for obesity management, is profiting from the U.S. public health crisis. He highlighted that Novo Nordisk's net worth stands at $570 billion, exceeding Denmark's GDP by over $100 billion, with potential profits reaching one trillion dollars by 2030. He called for a shift in focus from pharmaceuticals to reforming the food system to address obesity.

In response, a Novo Nordisk spokesperson clarified that semaglutide, the active ingredient in both Ozempic and Wegovy, is designed to support dietary changes and exercise, aiming to reduce cardiovascular risks for those with Type 2 diabetes or obesity. The spokesperson emphasized that obesity is a medical condition that requires intervention.

Kennedy has transitioned his focus from environmental advocacy to public health, advocating for food system reforms and addressing government policies contributing to chronic health issues. He is also a key supporter of former President Donald Trump and has been advising on health policy for a potential future administration.